EMA to broaden safety review of Sanofi's anti-arrhythmic, Multaq
This article was originally published in Scrip
Executive Summary
The European Medicines Agency (EMA) is to broaden its benefit-risk assessment of Sanofi's anti-arrhythmic drug, Multaq (dronedarone), to include a review of cardiovascular risk associated with the drug.